drug protocol number

CRN04894-12

drug sponsor

Crinetics Pharmaceuticals, Inc. / Ebkar Consultancy

drug study

Atumelnant

drug trial site

King Faisal Specialist Hospital and Research Center (Riyadh)

drug status

Ongoing

drug phase